Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn's disease
Source: SeekingAlpha
2026-02-17 06:15:51 ET
Read the full article on Seeking Alpha
For further details see:
Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Sanofi
NASDAQ: SNY
SNY Trading
-0.77% G/L:
$43.65 Last:
933,628 Volume:
$43.90 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
